BHVN

Biohaven Pharmaceutical Holding Company Ltd. [BHVN] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

BHVN Stock Summary

Top 10 Correlated ETFs

BHVN


Top 10 Correlated Stocks

BHVN


In the News

06:19 29 Mar 2024 BHVN

How Biohaven's experimental obesity drug could prevent muscle loss

Vlad Coric, Biohaven CEO, joins 'Fast Money' to discuss the weight loss drug wars and the company's experimental obesity drug.

05:31 29 Mar 2024 BHVN

Stocks to Watch: 3 Companies Working on Next-Gen Weight Loss Drugs

Everyone knows that America has a major obesity problem. Because of this, new anti-obesity drugs are going to generate a great deal of revenue and profits their companies.

06:00 29 Mar 2024 BHVN

Stocks to Watch: 3 Companies Working on Next-Gen Weight Loss Drugs

Everyone knows that America has a major obesity problem. Because of this, new anti-obesity drugs are going to generate a great deal of revenue and profits their companies.

07:00 29 Mar 2024 BHVN

Biohaven to Present at the 42nd Annual J.P. Morgan Healthcare Conference

NEW HAVEN, Conn. , Jan. 2, 2024 /PRNewswire/ -- Biohaven Ltd.

11:17 29 Mar 2024 BHVN

Is Biohaven Ltd. (BHVN) Outperforming Other Medical Stocks This Year?

Here is how Biohaven Ltd. (BHVN) and Blueprint Medicines (BPMC) have performed compared to their sector so far this year.

10:32 29 Mar 2024 BHVN

Biohaven Ltd. (BHVN) Is a Great Choice for 'Trend' Investors, Here's Why

If you are looking for stocks that are well positioned to maintain their recent uptrend, Biohaven Ltd. (BHVN) could be a great choice.

11:21 29 Mar 2024 BHVN

Are Medical Stocks Lagging Biohaven Ltd. (BHVN) This Year?

Here is how Biohaven Ltd. (BHVN) and Blueprint Medicines (BPMC) have performed compared to their sector so far this year.

10:33 29 Mar 2024 BHVN

Here's Why Momentum in Biohaven Ltd. (BHVN) Should Keep going

Biohaven Ltd. (BHVN) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move.

09:01 29 Mar 2024 BHVN

Biohaven (BHVN) Up on Positive Data from Autoimmune Disease Drug

Biohaven (BHVN) gains on preliminary data from a pre-clinical study on its pipeline candidate BHV-1300 targeting various autoimmune diseases.

12:00 29 Mar 2024 BHVN

Why Biohaven Stock Is Skyrocketing Today

Biohaven released a new investor presentation that featured encouraging information about drug candidate BHV-1300. The experimental drug showed promise in treating autoimmune diseases.

BHVN Financial details

Company Rating
Neutral
Market Cap
4.53B
Income
-408.17M
Revenue
0
Book val./share
5.35
Cash/share
4.79
Dividend
-
Dividend %
-
Employees
239
Optionable
No
Shortable
Yes
Earnings
10 May 2024
P/E
-7.02
Forward P/E
-9.7
PEG
1.26
P/S
-17.8
P/B
11.24
P/C
11.42
P/FCF
-12.97
Quick Ratio
4.08
Current Ratio
4.99
Debt / Equity
0.07
LT Debt / Equity
0.06
-
-
EPS (TTM)
-5.66
EPS next Y
-5.64
EPS next Q
-1.55
EPS this Y
-55.06%
EPS next Y
-0.41%
EPS next 5Y
-85.55%
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
20.67%
-
-
-
-
SMA20
18.92%
SMA50
25.31%
SMA100
99.75%
Inst Own
0.72%
Inst Trans
1.09%
ROA
-121%
ROE
-110%
ROC
-1.55%
Gross Margin
117%
Oper. Margin
230%
Profit Margin
216%
Payout
-
Shs Outstand
81.66M
Shs Float
69.87M
-
-
-
-
Target Price
23.5
52W Range
12.35-62.21
52W High
-11.79%
52W Low
+355.75%
RSI
51.03
Rel Volume
0.7
Avg Volume
1.2M
Volume
841.48K
Perf Week
-3.97%
Perf Month
16.07%
Perf Quarter
126.46%
Perf Half Y
209.86%
-
-
-
-
Beta
4.17402
-
-
Volatility
1.41%, 4.65%
Prev Close
-4.09%
Price
54.69
Change
-3.85%

BHVN Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0012.9100
Net income per share
-10.91-3.31-5.97-12.75-5.73
Operating cash flow per share
-7.78-2.12-4.07-6.65-4.66
Free cash flow per share
-7.83-2.2-4.1-7.57-4.7
Cash per share
6.538.537.510.45.38
Book value per share
-0.150.470.9712.046.01
Tangible book value per share
-0.151.052.0911.65.73
Share holders equity per share
-0.150.470.9712.046.01
Interest debt per share
-0.267.4916.351.510.43
Market cap
2.64B3.07B4.94B621.01M3.05B
Enterprise value
2.32B3.26B5.49B446.71M2.83B
P/E ratio
-4.99-25.87-23.09-1.09-7.47
Price to sales ratio
0010.6700
POCF ratio
-7-40.42-33.85-2.09-9.19
PFCF ratio
-6.95-39.04-33.63-1.83-9.1
P/B Ratio
-355.58182.97142.31.157.12
PTB ratio
-355.58182.97142.31.157.12
EV to sales
0011.8600
Enterprise value over EBITDA
-4.85-28.45-25.23-0.79-6.54
EV to operating cash flow
-6.16-42.86-37.63-1.5-8.53
EV to free cash flow
-6.12-41.39-37.39-1.32-8.45
Earnings yield
-0.2-0.04-0.04-0.92-0.13
Free cash flow yield
-0.14-0.03-0.03-0.55-0.11
Debt to equity
015.9818.080.130.07
Debt to assets
02.44.410.10.06
Net debt to EBITDA
0.66-1.62-2.530.310.51
Current ratio
4.9632.266.527.98
Interest coverage
37.6905.27409.760
Income quality
0.710.640.680.520.81
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
000.0800
Research and developement to revenue
000.3900
Intangibles to total assets
00.350.140.030.04
Capex to operating cash flow
0.010.040.010.140.01
Capex to revenue
00000
Capex to depreciation
0-37.46-0.67-29.63-0.9
Stock based compensation to revenue
000.1400
Graham number
6.135.9111.458.7727.84
ROIC
64.59-0.4-0.33-0.89-0.89
Return on tangible assets
-1.54-1.64-1.75-0.89-0.83
Graham Net
-0.7210.636.489.054.33
Working capital
262.11M59.88M52.89M496.95M387.02M
Tangible asset value
-7.42M37.69M74.9M518.98M408.19M
Net current asset value
-23.41M55.04M47.45M463.96M357.21M
Invested capital
015.9818.080.130.07
Average receivables
060.06M65.01M28.03M29.89M
Average payables
12.41M8.41M3.77M7.74M13.14M
Average inventory
019.78M23.15M31.45M28.08M
Days sales outstanding
007.8200
Days payables outstanding
013.98K19.012.82K1.69K
Days of inventory on hand
0200.56K26.8114.79K0
Receivables turnover
0046.6700
Payables turnover
00.0319.20.130.22
Inventory turnover
0013.610.020
ROE
71.23-7.07-6.16-1.06-0.95
Capex per share
-0.05-0.08-0.03-0.92-0.04

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
-3.530000
Net income per share
-3.3-1.03-1.32-1.5-1.81
Operating cash flow per share
-1.24-1.14-0.65-1.39-1.44
Free cash flow per share
-1.24-1.15-0.66-1.41-1.44
Cash per share
7.655.694.913.524.79
Book value per share
8.856.925.674.245.35
Tangible book value per share
8.536.635.383.965.11
Share holders equity per share
8.856.925.674.245.35
Interest debt per share
1.120.320.430.460.39
Market cap
844.75M931.71M1.63B1.78B3.42B
Enterprise value
670.46M836.43M1.51B1.7B3.2B
P/E ratio
-1.05-3.3-4.52-4.33-5.91
Price to sales ratio
-3.930000
POCF ratio
-11.2-12-36.77-18.74-29.78
PFCF ratio
-11.16-11.89-36.29-18.5-29.66
P/B Ratio
1.571.974.226.137.99
PTB ratio
1.571.974.226.137.99
EV to sales
-3.120000
Enterprise value over EBITDA
-3.15-10.99-16.42-15.35-20.96
EV to operating cash flow
-8.89-10.77-34.1-17.9-27.87
EV to free cash flow
-8.86-10.67-33.65-17.66-27.76
Earnings yield
-0.24-0.08-0.06-0.06-0.04
Free cash flow yield
-0.09-0.08-0.03-0.05-0.03
Debt to equity
0.130.060.080.110.07
Debt to assets
0.10.050.060.080.06
Net debt to EBITDA
0.821.251.290.721.43
Current ratio
6.524.784.944.997.98
Interest coverage
620.389.45000
Income quality
0.371.10.490.920.79
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
-0.360000
Research and developement to revenue
-0.640000
Intangibles to total assets
0.030.030.040.050.04
Capex to operating cash flow
00.010.010.010
Capex to revenue
00000
Capex to depreciation
-0.87-0.45-0.32-0.81-0.5
Stock based compensation to revenue
-0.540000
Graham number
25.6512.691311.9714.77
ROIC
-0.31-0.15-0.22-0.3-0.31
Return on tangible assets
-0.31-0.12-0.19-0.28-0.29
Graham Net
6.654.673.752.563.86
Working capital
496.95M430.47M346.27M248.39M387.02M
Tangible asset value
518.98M452.47M367.47M270.22M408.19M
Net current asset value
463.96M398.21M314.64M217.84M357.21M
Invested capital
0.130.060.080.110.07
Average receivables
28.74M44.98M26.24M10.86M13.36M
Average payables
7.72M12.58M13.25M10.78M12.55M
Average inventory
37.03M72.05M78.01M51.02M16.98M
Days sales outstanding
-19.310000
Days payables outstanding
26.951.7K1.35K999.241.48K
Days of inventory on hand
141.4110.36K7.66K3.57K0
Receivables turnover
-4.660000
Payables turnover
3.340.050.070.090.06
Inventory turnover
0.640.010.010.030
ROE
-0.37-0.15-0.23-0.35-0.34
Capex per share
0-0.01-0.01-0.02-0.01

BHVN Frequently Asked Questions

What is Biohaven Pharmaceutical Holding Company Ltd. stock symbol ?

Biohaven Pharmaceutical Holding Company Ltd. is a US stock , located in New haven of Ct and trading under the symbol BHVN

Is Biohaven Pharmaceutical Holding Company Ltd. buy or a sell ?

2 stock analysts have 2 predictions with a medium analyst target price of $23.5. The lowest prediction is $23 and the highest is $24

What is BHVN stock prediction ?

What is Biohaven Pharmaceutical Holding Company Ltd. stock quote today ?

Biohaven Pharmaceutical Holding Company Ltd. stock price is $54.69 today.

Is Biohaven Pharmaceutical Holding Company Ltd. stock public?

Yes, Biohaven Pharmaceutical Holding Company Ltd. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap